دورية أكاديمية
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials.
| العنوان: | Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. |
|---|---|
| المؤلفون: | Popoviciu MS; Faculty of Medicine and Pharmacy, University of Oradea, P-ta 1 Decembrie 10, 410073 Oradea, Romania., Păduraru L; Faculty of Medicine and Pharmacy, University of Oradea, P-ta 1 Decembrie 10, 410073 Oradea, Romania., Yahya G; Department of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Al Sharqia 44519, Egypt.; Department of Molecular Genetics, Faculty of Biology, Technical University of Kaiserslautern, Paul-Ehrlich Str. 24, 67663 Kaiserslautern, Germany., Metwally K; Department of Medicinal Chemistry, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.; Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt., Cavalu S; Faculty of Medicine and Pharmacy, University of Oradea, P-ta 1 Decembrie 10, 410073 Oradea, Romania. |
| المصدر: | International journal of molecular sciences [Int J Mol Sci] 2023 Jun 21; Vol. 24 (13). Date of Electronic Publication: 2023 Jun 21. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI, [2000- |
| مواضيع طبية MeSH: | Diabetes Mellitus, Type 2*/complications, Humans ; Hypoglycemic Agents/therapeutic use ; Exenatide ; Glucagon-Like Peptide 1/therapeutic use ; Peptides/pharmacology ; Glucagon-Like Peptide-1 Receptor ; Obesity/drug therapy ; Obesity/complications ; Weight Loss ; Liraglutide/therapeutic use ; Randomized Controlled Trials as Topic |
| مستخلص: | Obesity is a chronic disease with high prevalence and associated comorbidities, making it a growing global concern. These comorbidities include type 2 diabetes, hypertension, ventilatory dysfunction, arthrosis, venous and lymphatic circulation diseases, depression, and others, which have a negative impact on health and increase morbidity and mortality. GLP-1 agonists, used to treat type 2 diabetes, have been shown to be effective in promoting weight loss in preclinical and clinical studies. This review summarizes numerous studies conducted on the main drugs in the GLP-1 agonists class, outlining the maximum achievable weight loss. Our aim is to emphasize the active role and main outcomes of GLP-1 agonists in promoting weight loss, as well as in improving hyperglycemia, insulin sensitivity, blood pressure, cardio-metabolic, and renal protection. We highlight the pleiotropic effects of these medications, along with their indications, contraindications, and precautions for both diabetic and non-diabetic patients, based on long-term follow-up studies. |
| References: | Obes Res. 1999 Sep;7(5):477-84. (PMID: 10509605) Curr Obes Rep. 2015 Sep;4(3):303-10. (PMID: 26627487) Afr Health Sci. 2019 Sep;19(3):2591-2599. (PMID: 32127832) Curr Opin Cardiol. 2006 Jan;21(1):1-6. (PMID: 16355022) Diabetes Care. 2017 Apr;40(4):485-493. (PMID: 28188240) Lancet Diabetes Endocrinol. 2022 Mar;10(3):193-206. (PMID: 35131037) N Engl J Med. 2021 Aug 5;385(6):503-515. (PMID: 34170647) Diabetes Care. 2017 Jul;40(7):839-848. (PMID: 28473337) J Diabetes Complications. 2020 Apr;34(4):107520. (PMID: 31952996) Life (Basel). 2022 Jul 14;12(7):. (PMID: 35888142) Lancet. 2019 Jan 5;393(10166):31-39. (PMID: 30424892) Cardiovasc Diabetol. 2009 Feb 26;8:12. (PMID: 19245711) Lancet. 2009 Feb 7;373(9662):473-81. (PMID: 18819705) Neuroimage. 2007 Apr 1;35(2):511-7. (PMID: 17317222) Diabetes Care. 2016 Aug;39(8):1318-28. (PMID: 27222510) Mol Metab. 2021 Apr;46:101102. (PMID: 33068776) J Am Coll Cardiol. 2020 Feb 11;75(5):525-538. (PMID: 32029136) Int J Mol Sci. 2023 Jan 15;24(2):. (PMID: 36675217) Mini Rev Med Chem. 2009 Jun;9(6):664-73. (PMID: 19519492) Expert Rev Clin Pharmacol. 2021 Sep;14(9):1081-1089. (PMID: 34015974) N Engl J Med. 2022 Dec 15;387(24):2245-2257. (PMID: 36322838) Clin Sci (Lond). 2013 Feb;124(4):231-41. (PMID: 23126426) Drugs. 2008;68(2):147-63. (PMID: 18197723) Obes Sci Pract. 2017 Mar;3(1):3-14. (PMID: 28392927) Diabet Med. 2009 Sep;26(9):837-46. (PMID: 19719703) Dis Mon. 1990 Dec;36(12):641-731. (PMID: 2261844) Gastroenterology. 2017 May;152(7):1656-1670. (PMID: 28192107) N Engl J Med. 2015 Jul 2;373(1):11-22. (PMID: 26132939) Diabetes Care. 2012 Feb;35(2):252-8. (PMID: 22210563) Drug Des Devel Ther. 2022 May 25;16:1547-1559. (PMID: 35651477) Diabetes Obes Metab. 2011 Mar;13(3):207-20. (PMID: 21205109) Br J Pharmacol. 2012 May;166(1):27-41. (PMID: 21950636) Diabetologia. 2009 Oct;52(10):2046-55. (PMID: 19688338) Arch Intern Med. 2002 Sep 9;162(16):1867-72. (PMID: 12196085) Lancet. 2005 Nov 19;366(9499):1784-93. (PMID: 16298215) Expert Opin Pharmacother. 2019 Feb;20(2):133-141. (PMID: 30499733) Diabet Med. 2014 Feb;31(2):176-84. (PMID: 24117597) JAMA. 1994 Mar 16;271(11):840-4. (PMID: 8114238) Eur J Heart Fail. 2017 Jan;19(1):69-77. (PMID: 27790809) Curr Hypertens Rev. 2019;15(1):64-69. (PMID: 29737256) Fertil Steril. 2004 Jan;81(1):19-25. (PMID: 14711538) Ann Intern Med. 2020 Aug 18;173(4):278-286. (PMID: 32598218) Diabetes Obes Metab. 2021 Feb;23 Suppl 1:3-16. (PMID: 33621415) Expert Opin Biol Ther. 2016 Dec;16(12):1557-1569. (PMID: 27677385) Endocr Pract. 2011 May-Jun;17(3):345-55. (PMID: 21700561) Biomed Pharmacother. 2022 Aug;152:113225. (PMID: 35671584) J Clin Endocrinol Metab. 2011 May;96(5):1301-10. (PMID: 21307137) Diabetes Care. 2012 Apr;35(4):683-9. (PMID: 22357185) Front Pharmacol. 2022 Sep 14;13:935823. (PMID: 36188627) Diabet Med. 2009 Mar;26(3):268-78. (PMID: 19317822) Diabetes Care. 2016 Feb;39(2):222-30. (PMID: 26681713) Diabetes Obes Metab. 2017 Jul;19(7):979-988. (PMID: 28205322) Diabetes Obes Metab. 2017 Sep;19(9):1233-1241. (PMID: 28244632) Am J Manag Care. 2010 Aug;16(7 Suppl):S187-94. (PMID: 20809667) Diabetes Care. 2013 Sep;36(9):2543-50. (PMID: 23536584) Diabetes Care. 2013 Oct;36(10):2945-51. (PMID: 23698396) N Engl J Med. 2021 May 6;384(18):1719-1730. (PMID: 33951361) Endocr Pract. 2016 Jul;22 Suppl 3:1-203. (PMID: 27219496) Curr Pulmonol Rep. 2015 Mar 1;4(1):42-55. (PMID: 26029497) Postgrad Med J. 2020 Mar;96(1133):156-161. (PMID: 31801807) N Engl J Med. 2022 Jul 21;387(3):205-216. (PMID: 35658024) Endocr Pract. 2013 Sep-Oct;19(5):864-74. (PMID: 24014010) Nat Med. 2022 Oct;28(10):2083-2091. (PMID: 36216945) Drug Discov Today. 2013 Sep;18(17-18):807-17. (PMID: 23726889) Lancet. 2013 Jan 12;381(9861):117-24. (PMID: 23141817) Diabetes Metab Syndr Obes. 2021 Aug 10;14:3567-3602. (PMID: 34413662) Diabetes Care. 2009 Jan;32(1):84-90. (PMID: 18931095) Diabetes Obes Metab. 2017 Nov;19(11):1529-1536. (PMID: 28386912) Lancet. 2002 Mar 9;359(9309):824-30. (PMID: 11897280) Oncogene. 2004 Aug 23;23(38):6365-78. (PMID: 15322511) BMJ Open Gastroenterol. 2020 Aug;7(1):. (PMID: 32784205) Diabetes Care. 2012 Jun;35(6):1225-31. (PMID: 22432104) Lancet. 2006 Nov 11;368(9548):1696-705. (PMID: 17098089) Int J Obes (Lond). 2016 Apr;40(4):622-32. (PMID: 26499438) Lancet. 2021 Jul 10;398(10295):143-155. (PMID: 34186022) Front Endocrinol (Lausanne). 2021 Apr 09;12:609110. (PMID: 33897616) Int J Cancer. 2003 Aug 10;106(1):96-102. (PMID: 12794763) Expert Opin Pharmacother. 2020 Feb;21(3):275-285. (PMID: 31790314) Mol Cell. 2020 Nov 5;80(3):485-500.e7. (PMID: 33027691) J Endocrinol. 2014 Mar 07;221(1):T1-16. (PMID: 24323912) Diabetes Care. 2013 Sep;36(9):2489-96. (PMID: 23628617) Diabetes Obes Metab. 2013 Nov;15(11):1000-7. (PMID: 23627775) Diabetes Res Clin Pract. 2014 Feb;103(2):269-75. (PMID: 24485345) Endocr Pract. 2012 Sep-Oct;18(5):642-8. (PMID: 23047927) Diabet Med. 2011 Jun;28(6):705-14. (PMID: 21434995) JAMA. 2021 Apr 13;325(14):1414-1425. (PMID: 33755728) Med. 2020 Dec 18;1(1):33-42. (PMID: 32838359) Lancet Diabetes Endocrinol. 2016 Mar;4(3):221-232. (PMID: 26656289) Diabetes Obes Metab. 2018 Nov;20(11):2557-2564. (PMID: 29892986) Int J Obes. 1991 Jun;15(6):397-406. (PMID: 1885263) J Vasc Surg. 2003 Jan;37(1):79-85. (PMID: 12514581) Lancet. 2017 Apr 8;389(10077):1399-1409. (PMID: 28237263) Am J Manag Care. 2016 Jun;22(7 Suppl):s176-85. (PMID: 27356115) Lancet. 2009 Nov 7;374(9701):1606-16. (PMID: 19853906) Lancet. 2009 Jul 4;374(9683):39-47. (PMID: 19515413) N Engl J Med. 2016 Jul 28;375(4):311-22. (PMID: 27295427) J Clin Endocrinol Metab. 2022 Mar 24;107(4):e1339-e1347. (PMID: 34865050) Biol Trace Elem Res. 2015 Dec;168(2):311-20. (PMID: 26006095) Diabetes Care. 2011 Jan;34(1):132-8. (PMID: 20870968) Diabetes Care. 2005 Sep;28(9):2322-5. (PMID: 16123512) Diabetes Obes Metab. 2018 Feb;20 Suppl 1:5-21. (PMID: 29364588) Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1267-1271. (PMID: 27607315) Circulation. 2022 Feb 22;145(8):575-585. (PMID: 34903039) Nature. 1983 Apr 21;302(5910):703-6. (PMID: 6300693) Lancet. 2021 Mar 13;397(10278):971-984. (PMID: 33667417) IDrugs. 2009 Aug;12(8):503-13. (PMID: 19629885) Ann Intern Med. 1995 Apr 1;122(7):481-6. (PMID: 7872581) Diabetes Care. 2007 Jun;30(6):1487-93. (PMID: 17353504) N Engl J Med. 2005 Oct 6;353(14):1454-62. (PMID: 16207847) Lancet Diabetes Endocrinol. 2022 Sep;10(9):623-633. (PMID: 35914543) J Diabetes Complications. 2014 May-Jun;28(3):386-92. (PMID: 24650952) J Med Chem. 2015 Sep 24;58(18):7370-80. (PMID: 26308095) Arch Intern Med. 1999 Nov 22;159(21):2582-8. (PMID: 10573048) Clin Diabetes. 2020 Jan;38(1):109-111. (PMID: 31975761) Int J Obes (Lond). 2014 May;38(5):689-97. (PMID: 23942319) Lancet. 2021 Nov 13;398(10313):1811-1824. (PMID: 34672967) N Engl J Med. 2021 Mar 18;384(11):989-1002. (PMID: 33567185) Pediatrics. 1998 Sep;102(3):E29. (PMID: 9724677) BMJ Open Diabetes Res Care. 2020 Oct;8(1):. (PMID: 33037036) Diabetes Obes Metab. 2017 Mar;19(3):336-347. (PMID: 27860132) Diabetes Care. 2009 Jul;32(7):1224-30. (PMID: 19289857) Exp Ther Med. 2021 Oct;22(4):1167. (PMID: 34504612) Lancet Diabetes Endocrinol. 2022 Sep;10(9):634-644. (PMID: 35914542) JAMA. 2022 Jan 11;327(2):138-150. (PMID: 35015037) Diabetes Obes Metab. 2018 Jul;20(7):1602-1614. (PMID: 29473704) Metabolism. 2001 Jul;50(7):795-800. (PMID: 11436184) J Diabetes Complications. 2019 Mar;33(3):223-230. (PMID: 30600137) N Engl J Med. 1995 Mar 9;332(10):621-8. (PMID: 7632212) ChemMedChem. 2018 Apr 6;13(7):662-671. (PMID: 29430842) Expert Opin Drug Saf. 2015 Feb;14(2):207-18. (PMID: 25496749) Diabetes. 2014 Apr;63(4):1174-8. (PMID: 24651798) Am J Med. 1999 Jun;106(6):642-9. (PMID: 10378622) JAMA. 2021 Apr 13;325(14):1403-1413. (PMID: 33625476) JAMA. 2022 Feb 8;327(6):534-545. (PMID: 35133415) Lancet. 2021 Aug 14;398(10300):583-598. (PMID: 34370970) Clin Pharmacokinet. 2016 Jun;55(6):657-72. (PMID: 26597252) Diabetes Care. 2013 Sep;36(9):2497-503. (PMID: 23564915) |
| فهرسة مساهمة: | Keywords: GLP-1 agonists; Lixisenatide; exenatide; liraglutide; obesity; semaglutide; tirzepatide; type 2 diabetes; weight loss |
| المشرفين على المادة: | 0 (Hypoglycemic Agents) 9P1872D4OL (Exenatide) 89750-14-1 (Glucagon-Like Peptide 1) 0 (Peptides) 0 (Glucagon-Like Peptide-1 Receptor) 839I73S42A (Liraglutide) |
| تواريخ الأحداث: | Date Created: 20230714 Date Completed: 20230717 Latest Revision: 20230718 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10341852 |
| DOI: | 10.3390/ijms241310449 |
| PMID: | 37445623 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1422-0067 |
|---|---|
| DOI: | 10.3390/ijms241310449 |